RU99110192A - METHOD OF USE OF CYCLOXYGENASE-2 INHIBITORS FOR TREATMENT AND PREVENTION OF NEOPLASION - Google Patents
METHOD OF USE OF CYCLOXYGENASE-2 INHIBITORS FOR TREATMENT AND PREVENTION OF NEOPLASIONInfo
- Publication number
- RU99110192A RU99110192A RU99110192/14A RU99110192A RU99110192A RU 99110192 A RU99110192 A RU 99110192A RU 99110192/14 A RU99110192/14 A RU 99110192/14A RU 99110192 A RU99110192 A RU 99110192A RU 99110192 A RU99110192 A RU 99110192A
- Authority
- RU
- Russia
- Prior art keywords
- benzenesulfonamide
- phenyl
- trifluoromethyl
- methylsulfonyl
- fluorophenyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 4
- 230000002265 prevention Effects 0.000 title claims 2
- -1 heterocyclic radical Chemical class 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000003254 radicals Chemical class 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- WAZQAZKAZLXFMK-UHFFFAOYSA-N Deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 claims 5
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 208000004804 Adenomatous Polyps Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- ZJOUYQCSZYKGKU-UHFFFAOYSA-N 3-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=NC=CC=2)=NC(C(F)(F)F)=C1 ZJOUYQCSZYKGKU-UHFFFAOYSA-N 0.000 claims 2
- NSRMOHFGSWCCFK-UHFFFAOYSA-N 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=CN=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 NSRMOHFGSWCCFK-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 230000002496 gastric Effects 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 2
- LWIFWMYFVZYWMS-UHFFFAOYSA-N 1,2-difluoro-3-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C(=C(F)C=CC=2)F)CCC1 LWIFWMYFVZYWMS-UHFFFAOYSA-N 0.000 claims 1
- RFPZMXMBYMEQHZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=CC=C1C1=CC=C(F)C=C1 RFPZMXMBYMEQHZ-UHFFFAOYSA-N 0.000 claims 1
- GWMFOHRUWPDLIP-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)-2-phenyl-4-(trifluoromethyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC=CC=2)=NC(C(F)(F)F)=C1 GWMFOHRUWPDLIP-UHFFFAOYSA-N 0.000 claims 1
- HUVCBGHNHBHJBX-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-methylsulfonylbenzene Chemical compound C1C(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 HUVCBGHNHBHJBX-UHFFFAOYSA-N 0.000 claims 1
- MBUIIOVYVHAZOU-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-methylsulfonylbenzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(Cl)=CC=2)CCC1 MBUIIOVYVHAZOU-UHFFFAOYSA-N 0.000 claims 1
- SZHKSRZKPUOAGO-UHFFFAOYSA-N 1-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]-4-(trifluoromethyl)benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(=CC=2)C(F)(F)F)CCC1 SZHKSRZKPUOAGO-UHFFFAOYSA-N 0.000 claims 1
- BPWDIXPFAHESAF-UHFFFAOYSA-N 1-[3,3-dimethyl-5-(4-methylsulfonylphenyl)cyclopenta-1,4-dien-1-yl]-4-fluorobenzene Chemical compound C=1C(C)(C)C=C(C=2C=CC(F)=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 BPWDIXPFAHESAF-UHFFFAOYSA-N 0.000 claims 1
- VKUCTHVTLJBHDT-UHFFFAOYSA-N 1-[4,4-dimethyl-2-(4-methylsulfonylphenyl)cyclopenten-1-yl]-4-fluorobenzene Chemical compound C1C(C)(C)CC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 VKUCTHVTLJBHDT-UHFFFAOYSA-N 0.000 claims 1
- XKSNSSNGFIQSFK-UHFFFAOYSA-N 1-ethyl-4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)pyrazole Chemical compound FC(F)(F)C=1N(CC)N=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=1C1=CC=C(F)C=C1 XKSNSSNGFIQSFK-UHFFFAOYSA-N 0.000 claims 1
- GJGZQTGPOKPFES-UHFFFAOYSA-N 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)CCC1 GJGZQTGPOKPFES-UHFFFAOYSA-N 0.000 claims 1
- RAUHMMADXJJVRP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 RAUHMMADXJJVRP-UHFFFAOYSA-N 0.000 claims 1
- JQDLRYPRLMZWFM-UHFFFAOYSA-N 1-methylsulfanyl-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(SC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 JQDLRYPRLMZWFM-UHFFFAOYSA-N 0.000 claims 1
- KSFMAASFLCWROX-UHFFFAOYSA-N 2,4-dichloro-1-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C(=CC(Cl)=CC=2)Cl)CCC1 KSFMAASFLCWROX-UHFFFAOYSA-N 0.000 claims 1
- VCLNQQUCGTWUKD-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2C(=CC=CC=2)Cl)S1 VCLNQQUCGTWUKD-UHFFFAOYSA-N 0.000 claims 1
- NWVGCEQIXKQQPS-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=C(F)C(F)=CC=2)=NC(C(F)(F)F)=C1 NWVGCEQIXKQQPS-UHFFFAOYSA-N 0.000 claims 1
- SOOKCKQNOCMHPV-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2C=C(Cl)C(F)=CC=2)S1 SOOKCKQNOCMHPV-UHFFFAOYSA-N 0.000 claims 1
- YLFBPUKBMRJHLM-UHFFFAOYSA-N 2-(3-chlorophenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=C(Cl)C=CC=2)=NC(C(F)(F)F)=C1 YLFBPUKBMRJHLM-UHFFFAOYSA-N 0.000 claims 1
- UFSJAWLGOHKVBH-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=C(F)C(OC)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(C)(=O)=O)C=C1 UFSJAWLGOHKVBH-UHFFFAOYSA-N 0.000 claims 1
- MEAMLMDMYOLDGW-UHFFFAOYSA-N 2-(3-fluoro-5-methylphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound CC1=CC(F)=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 MEAMLMDMYOLDGW-UHFFFAOYSA-N 0.000 claims 1
- RSABMOYFBOLDLO-UHFFFAOYSA-N 2-(3-methylphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound CC1=CC=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 RSABMOYFBOLDLO-UHFFFAOYSA-N 0.000 claims 1
- HIHJKGFABKMSHO-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-methyl-1-(4-methylsulfonylphenyl)imidazole Chemical compound N=1C(C)=CN(C=2C=CC(=CC=2)S(C)(=O)=O)C=1C1=CC=C(F)C=C1 HIHJKGFABKMSHO-UHFFFAOYSA-N 0.000 claims 1
- PEUVGLHBVHFKPT-UHFFFAOYSA-N 2-(4-methylphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(C)(=O)=O)C=C1 PEUVGLHBVHFKPT-UHFFFAOYSA-N 0.000 claims 1
- KCPPTAVUOWTXDZ-UHFFFAOYSA-N 2-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2N=CC=CC=2)=NC(C(F)(F)F)=C1 KCPPTAVUOWTXDZ-UHFFFAOYSA-N 0.000 claims 1
- YRVHNSYUGHFPFQ-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)pyrazol-1-yl]-N-phenylacetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1C(F)(F)F)C=2C=CC(F)=CC=2)=NN1CC(=O)NC1=CC=CC=C1 YRVHNSYUGHFPFQ-UHFFFAOYSA-N 0.000 claims 1
- AGCRHVNIFLDQNI-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-oxazol-2-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(CC(O)=O)O1 AGCRHVNIFLDQNI-UHFFFAOYSA-N 0.000 claims 1
- NECDCTAHUMBLQG-UHFFFAOYSA-N 2-bromo-6-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=C(Br)N=C1C1=CC=C(F)C=C1 NECDCTAHUMBLQG-UHFFFAOYSA-N 0.000 claims 1
- KYNAWJZJGXEMMS-UHFFFAOYSA-N 2-chloro-1-methoxy-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=C(Cl)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 KYNAWJZJGXEMMS-UHFFFAOYSA-N 0.000 claims 1
- ZTHDILTXFNKYMK-UHFFFAOYSA-N 2-methyl-4-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound C1=NC(C)=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 ZTHDILTXFNKYMK-UHFFFAOYSA-N 0.000 claims 1
- TZUKXDRCVJCLLL-UHFFFAOYSA-N 2-methyl-5-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound C1=NC(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(C)(=O)=O)C=C1 TZUKXDRCVJCLLL-UHFFFAOYSA-N 0.000 claims 1
- UJAMUMWHXRVKDM-UHFFFAOYSA-N 2-methyl-6-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound CC1=CC=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=N1 UJAMUMWHXRVKDM-UHFFFAOYSA-N 0.000 claims 1
- AMTZZFUBJIWXKB-UHFFFAOYSA-N 2-tert-butyl-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-oxazole Chemical compound O1C(C(C)(C)C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 AMTZZFUBJIWXKB-UHFFFAOYSA-N 0.000 claims 1
- OCROGSYJFYKXMO-UHFFFAOYSA-N 3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-6-prop-2-ynoxy-2-(trifluoromethyl)pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(OCC#C)=NC(C(F)(F)F)=C1C1=CC=C(F)C=C1 OCROGSYJFYKXMO-UHFFFAOYSA-N 0.000 claims 1
- VTXIMXSYKSVSGP-UHFFFAOYSA-N 3-(4-fluorophenyl)-6-methoxy-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)pyridine Chemical compound C=1C=C(F)C=CC=1C=1C(C(F)(F)F)=NC(OC)=CC=1C1=CC=C(S(C)(=O)=O)C=C1 VTXIMXSYKSVSGP-UHFFFAOYSA-N 0.000 claims 1
- RBIMSEGCQFORTH-UHFFFAOYSA-N 4-(2-methyl-4-phenyl-1,3-oxazol-5-yl)benzenesulfonamide Chemical compound O1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 RBIMSEGCQFORTH-UHFFFAOYSA-N 0.000 claims 1
- FQJOALWXRJKJFW-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)-1,3-oxazole Chemical compound O1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 FQJOALWXRJKJFW-UHFFFAOYSA-N 0.000 claims 1
- HLSMDYHXAPYMPD-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1C(F)(F)F)C=2C=CC(F)=CC=2)=NN1CCC1=CC=CC=C1 HLSMDYHXAPYMPD-UHFFFAOYSA-N 0.000 claims 1
- YTLPYUWXEWWKRU-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-1-(2-phenylethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1)C=2C=CC(F)=CC=2)=NN1CCC1=CC=CC=C1 YTLPYUWXEWWKRU-UHFFFAOYSA-N 0.000 claims 1
- OHEHAWXOSFKVTI-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-1-prop-2-enyl-5-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NN(CC=C)C(C(F)(F)F)=C1C1=CC=C(F)C=C1 OHEHAWXOSFKVTI-UHFFFAOYSA-N 0.000 claims 1
- KHZNXVYATAUMBJ-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1-phenyl-3-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)C(C(F)(F)F)=NN1C1=CC=CC=C1 KHZNXVYATAUMBJ-UHFFFAOYSA-N 0.000 claims 1
- SAVMISCIBLZUAE-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C(F)(F)F)S1 SAVMISCIBLZUAE-UHFFFAOYSA-N 0.000 claims 1
- QDPWDPOAKFQYJR-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-phenyl-1,3-oxazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2C=CC=CC=2)O1 QDPWDPOAKFQYJR-UHFFFAOYSA-N 0.000 claims 1
- ISMZMNIRFHOTII-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-thiophen-2-yl-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2SC=CC=2)S1 ISMZMNIRFHOTII-UHFFFAOYSA-N 0.000 claims 1
- DEXPHZXXTBGSGZ-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-N-propyl-1,3-thiazol-2-amine Chemical compound S1C(NCCC)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 DEXPHZXXTBGSGZ-UHFFFAOYSA-N 0.000 claims 1
- UUVBGFWWLRWVAV-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-5-thiophen-2-yl-2-(trifluoromethyl)-1H-imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2SC=CC=2)NC(C(F)(F)F)=N1 UUVBGFWWLRWVAV-UHFFFAOYSA-N 0.000 claims 1
- TXRHVHRTTYBPNN-UHFFFAOYSA-N 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]benzenesulfonamide Chemical compound FC(F)(F)C=1N(CC)N=C(C=2C=CC(=CC=2)S(N)(=O)=O)C=1C1=CC=C(F)C=C1 TXRHVHRTTYBPNN-UHFFFAOYSA-N 0.000 claims 1
- JPWKLILKLRXARO-UHFFFAOYSA-N 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=NC=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 JPWKLILKLRXARO-UHFFFAOYSA-N 0.000 claims 1
- IRKVLCOCTJNMRX-UHFFFAOYSA-N 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=C(Cl)C(F)=CC=2)CCC1 IRKVLCOCTJNMRX-UHFFFAOYSA-N 0.000 claims 1
- PHBYRHUAGNXCFU-UHFFFAOYSA-N 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 PHBYRHUAGNXCFU-UHFFFAOYSA-N 0.000 claims 1
- RSYPHTZEXAJUHX-UHFFFAOYSA-N 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(N)(=O)=O)CCC1 RSYPHTZEXAJUHX-UHFFFAOYSA-N 0.000 claims 1
- UFAWCYIJMWUQEO-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide Chemical compound C1C(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 UFAWCYIJMWUQEO-UHFFFAOYSA-N 0.000 claims 1
- SEOHAKCJVHNLFU-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC(Cl)=CC=2)CCC1 SEOHAKCJVHNLFU-UHFFFAOYSA-N 0.000 claims 1
- NTIRVNBDXWODFR-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide Chemical compound C1C(C)(C)CC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 NTIRVNBDXWODFR-UHFFFAOYSA-N 0.000 claims 1
- PISBIZMMMDTULP-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC(F)=CC=2)CCC1 PISBIZMMMDTULP-UHFFFAOYSA-N 0.000 claims 1
- JSMWYOPCPZTWAA-UHFFFAOYSA-N 4-[3,5-bis(4-methoxyphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC(=CC=2)S(N)(=O)=O)C(C=2C=CC(OC)=CC=2)=C1 JSMWYOPCPZTWAA-UHFFFAOYSA-N 0.000 claims 1
- YDUQOLMYSBDZFO-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-phenylpyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C=2C=CC=CC=2)=N1 YDUQOLMYSBDZFO-UHFFFAOYSA-N 0.000 claims 1
- RSVKRWJGUDWYLS-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)spiro[2.4]hept-5-en-6-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C1)=C(C=2C=CC(F)=CC=2)CC11CC1 RSVKRWJGUDWYLS-UHFFFAOYSA-N 0.000 claims 1
- BOEJXBGCXOGVPM-UHFFFAOYSA-N 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C(C1)=C(C=2C=CC(=CC=2)S(N)(=O)=O)CC11CC1 BOEJXBGCXOGVPM-UHFFFAOYSA-N 0.000 claims 1
- CHJMEHVGESAPSR-UHFFFAOYSA-N 4-fluoro-2-methyl-1-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound CC1=CC(F)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 CHJMEHVGESAPSR-UHFFFAOYSA-N 0.000 claims 1
- JHBIMJKLBUMNAU-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 JHBIMJKLBUMNAU-UHFFFAOYSA-N 0.000 claims 1
- ZPMVBXDFUCFRLF-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-methyl-4-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound S1C(C)=NC(C=2C=CC(=CC=2)S(C)(=O)=O)=C1C1=CC=C(F)C=C1 ZPMVBXDFUCFRLF-UHFFFAOYSA-N 0.000 claims 1
- IPSWLWPSIVTXOW-UHFFFAOYSA-N 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(C(F)(F)F)=N1 IPSWLWPSIVTXOW-UHFFFAOYSA-N 0.000 claims 1
- MOHZCSPHJUIPJF-UHFFFAOYSA-N 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)-1H-imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)NC(C(F)(F)F)=N1 MOHZCSPHJUIPJF-UHFFFAOYSA-N 0.000 claims 1
- VZCIAZMKVAJRCL-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C1)=C(C=2C=CC(F)=CC=2)CC11CC1 VZCIAZMKVAJRCL-UHFFFAOYSA-N 0.000 claims 1
- CJAWPKAYKMKKAD-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylsulfonylphenyl)spiro[2.4]hepta-4,6-diene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1)C=2C=CC(F)=CC=2)=CC11CC1 CJAWPKAYKMKKAD-UHFFFAOYSA-N 0.000 claims 1
- IXOVKZSZDFZOQP-UHFFFAOYSA-N 6-(3,5-dichloro-4-methoxyphenyl)-5-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene Chemical compound C1=C(Cl)C(OC)=C(Cl)C=C1C(C1)=C(C=2C=CC(=CC=2)S(C)(=O)=O)CC11CC1 IXOVKZSZDFZOQP-UHFFFAOYSA-N 0.000 claims 1
- OBDYUVYOLLAPQL-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)-5-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C1)=C(C=2C=C(Cl)C(F)=CC=2)CC11CC1 OBDYUVYOLLAPQL-UHFFFAOYSA-N 0.000 claims 1
- NATBBDVYNBNABG-UHFFFAOYSA-N 6-(3-chloro-4-methoxyphenyl)-5-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene Chemical compound C1=C(Cl)C(OC)=CC=C1C(C1)=C(C=2C=CC(=CC=2)S(C)(=O)=O)CC11CC1 NATBBDVYNBNABG-UHFFFAOYSA-N 0.000 claims 1
- OIXFVGJRZFMIBH-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methoxy-5-(4-methylsulfonylphenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C=C(C#N)C(OC)=NC=1C1=CC=C(F)C=C1 OIXFVGJRZFMIBH-UHFFFAOYSA-N 0.000 claims 1
- JSEDBZHLLXWYHV-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-phenylpyridine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=C(C=2C=CC=CC=2)N=C1C1=CC=C(F)C=C1 JSEDBZHLLXWYHV-UHFFFAOYSA-N 0.000 claims 1
- WSMKPFRGAQKKFX-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(4-methylsulfonylphenyl)spiro[3.4]oct-6-ene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C1)=C(C=2C=CC(F)=CC=2)CC11CCC1 WSMKPFRGAQKKFX-UHFFFAOYSA-N 0.000 claims 1
- QFRDGIZQIJYOJO-UHFFFAOYSA-N 6-bromo-3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(Br)=NC(C(F)(F)F)=C1C1=CC=C(F)C=C1 QFRDGIZQIJYOJO-UHFFFAOYSA-N 0.000 claims 1
- XGONYOLEZPFZPF-UHFFFAOYSA-N 6-ethoxy-3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)pyridine Chemical compound C=1C=C(F)C=CC=1C=1C(C(F)(F)F)=NC(OCC)=CC=1C1=CC=C(S(C)(=O)=O)C=C1 XGONYOLEZPFZPF-UHFFFAOYSA-N 0.000 claims 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- VMWJCFLUSKZZDX-UHFFFAOYSA-N N,N-dimethylmethanamine Chemical group [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims 1
- HKYOGYJVZLWKLN-UHFFFAOYSA-N N-[5-(3,4-difluorophenyl)-2-(trifluoromethyl)-1,3-oxazol-4-yl]benzenesulfonamide Chemical compound C1=C(F)C(F)=CC=C1C1=C(NS(=O)(=O)C=2C=CC=CC=2)N=C(C(F)(F)F)O1 HKYOGYJVZLWKLN-UHFFFAOYSA-N 0.000 claims 1
- HCSFFMYIHYYVTK-UHFFFAOYSA-N N-benzyl-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(NCC=2C=CC=CC=2)S1 HCSFFMYIHYYVTK-UHFFFAOYSA-N 0.000 claims 1
- 102000035443 Peptidases Human genes 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- ACMHHODLBDGSDF-UHFFFAOYSA-N ethyl 2-[4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)pyrazol-1-yl]acetate Chemical compound FC(F)(F)C=1N(CC(=O)OCC)N=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=1C1=CC=C(F)C=C1 ACMHHODLBDGSDF-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 230000003054 hormonal Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000000677 immunologic agent Substances 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000001613 neoplastic Effects 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Claims (20)
где R4 представляет низший галогеналкил;
R5 представляет гидридо и
R6 представляет фенил, необязательно замещенный в замещаемом положении одним или несколькими радикалами, выбранными из галогена, низшего алкилтио, низшего алкилсульфонила, циано, нитро, низшего галогеналкила, низшего алкила, гидроксила, низшего алкенила, низшего гидроксиалкила, карбоксила, низшего циклоалкила, низшего алкиламино, низшего диалкиламино, низшего алкоксикарбонила, аминокарбонила, низшего алкокси, низшего галогеналкокси, сульфамила, пяти- или шестичленного гетероциклического радикала или амино;
или его фармацевтически приемлемой соли или фармацевтически приемлемого производного для изготовления лекарственного средства для лечения неоплазии у субъекта.1. The use of the compounds of formula II
where R 4 is lower haloalkyl;
R 5 is hydrido and
R 6 is phenyl, optionally substituted in a substitutable position by one or more radicals selected from halogen, lower alkylthio, lower alkylsulfonyl, cyano, nitro, lower haloalkyl, lower alkyl, hydroxyl, lower alkenyl, lower hydroxyalkyl, carboxyl, lower cycloalkyl, lower alkyl , dialkylamino, lower alkoxycarbonyl, aminocarbonyl, lower alkoxy, lower haloalkoxy, sulfamyl, five- or six-membered heterocyclic radical, or amino;
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for treating neoplasia in a subject.
4-[5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-{5-фенил-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-фторфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[5-(4-хлорфенил)-3-(дифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метилфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-(4-метилфенил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-фенил-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-(4-метоксифелил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[3-(дифторметил)-5-(3-фтор-4-метоксифенил)-1Н-пиразол1-ил] бензолсульфонамида;
4-[5-(3-фтор-4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида и
4-[5-(4-(N, N-диметиламино)фенил)-3-(трифторметил)-1H-пиразол-1-ил] бензолсульфонамида.2. The use according to claim 1, in which the compound is selected from the group of compounds and their pharmaceutically acceptable salts, consisting of
4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- {5-phenyl-3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [5- (4-fluorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-chlorophenyl) -3- (difluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (4-methylphenyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5-phenyl-1H-pyrazol-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (4-methoxyfelyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (3-fluoro-4-methoxyphenyl) -1H-pyrazol1-yl] benzenesulfonamide;
4- [5- (3-fluoro-4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide and
4- [5- (4- (N, N-dimethylamino) phenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide.
где R4 представляет низший галогеналкил;
R5 представляет гидридо и
R6 представляет фенил, необязательно замещенный в замещаемом положении одним или несколькими радикалами, выбранными из галогена, низшего алкилтио, низшего алкилсульфонила, циано, нитро, низшего галогеналкила, низшего алкила, гидроксила, низшего алкенила, низшего гидроксиалкила, карбоксила, низшего циклоалкила, низшего алкиламино, низшего диалкиламино, низшего алкоксикарбонила, аминокарбонила, низшего алкокси, низшего галогеналкокси, сульфамила, пяти- или шестичленного гетероциклического радикала или амино; или его фармацевтически приемлемой соли или фармацевтически приемлемого производного для изготовления лекарственного средства для профилактики неоплазии, выбранной из аденоматозных полипов, рака желудочно-кишечного тракта, рака печени, рака мочевого пузыря, рака шейки матки, рака предстательной железы, рака легкого, рака молочной железы и рака кожи, у субъекта, нуждающегося в такой профилактике.7. The use of the compounds of formula II
where R 4 is lower haloalkyl;
R 5 is hydrido and
R 6 is phenyl, optionally substituted in a substitutable position by one or more radicals selected from halogen, lower alkylthio, lower alkylsulfonyl, cyano, nitro, lower haloalkyl, lower alkyl, hydroxyl, lower alkenyl, lower hydroxyalkyl, carboxyl, lower cycloalkyl, lower alkyl , dialkylamino, lower alkoxycarbonyl, aminocarbonyl, lower alkoxy, lower haloalkoxy, sulfamyl, five- or six-membered heterocyclic radical, or amino; or a pharmaceutically acceptable salt or pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the prevention of neoplasia selected from adenomatous polyps, gastrointestinal cancer, liver cancer, bladder cancer, cervical cancer, prostate cancer, lung cancer, breast cancer and skin cancer in a subject in need of such prophylaxis.
4-[5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-фенил-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-фторфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[5-(4-хлорфенил)-3-(дифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метилфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-(4-метилфенил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-фенил-1Н-пиразол-1-ил]бенволсульфонамида;
4-[3-(дифторметил)-5-(4-метоксифенил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[3-(дифторметил)-5-(3-фтор-4-метоксифенил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(3-фтор-4-метоксифенил)-3-(трифторметил)-1H-пиразол-1-ил] бензолсульфонамида и
4-[5-(4-(N, N-диметиламино)фенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида.8. The use according to claim 7, in which the compound is selected from the group of compounds and their pharmaceutically acceptable salts, consisting of:
4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5-phenyl-3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [5- (4-fluorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-chlorophenyl) -3- (difluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (4-methylphenyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5-phenyl-1H-pyrazol-1-yl] benvolsulfonamide;
4- [3- (difluoromethyl) -5- (4-methoxyphenyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (3-fluoro-4-methoxyphenyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [5- (3-fluoro-4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide and
4- [5- (4- (N, N-dimethylamino) phenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide.
где А представляет заместитель, выбранный из частично ненасыщенных или ненасыщенных гетероциклильных и частично ненасыщенных или ненасыщенных карбоциклических колец;
R1 представляет по крайней мере один заместитель, выбранный из гетероциклила, циклоалкила, циклоалкенила или арила, причем R1 является необязательно замещенным в замещаемом положении одним или несколькими радикалами, выбранными из алкила, галогеналкила, циано, карбоксила, алкоксикарбонила, гидроксила, гидроксиалкила, галогеналкокси, амино, алкиламино, ариламино, нитро, алкоксиалкила, алкилсульфинила, галогена, алкокси и алкилтио;
R2 представляет метил или амино; и
R3 представляет радикал, выбранный из гидридо, галогена, алкила, алкенила, алкинила, оксо, циано, карбоксила, цианоалкила, гетероциклилокси, алкилокси, алкилтио, алкилкарбонила, циклоалкила, арила, галогеналкила, гетероциклила, циклоалкенила, аралкила, гетероциклилалкила, ацила, алкилтиоалкила, гидроксиалкила, алкоксикарбонила, арилкарбонила, аралкилкарбонила, аралкенила, алкоксиалкила, арилтиоалкила, арилоксиалкила, аралкилтиоалкила, аралкоксиалкила, алкоксиаралкоксиалкила, алкоксикарбонилалкила, аминокарбонила, аминокарбонилалкила, алкиламинокарбонила, N-ариламинокарбонила, N-алкил-N-ариламинокарбонила, алкиламинокарбонилалкила, карбоксиалкила, алкиламино, N-ариламино, N-аралкиламино, N-алкил-N-аралкиламино, N-алкил-N-ариламино, аминоалкила, алкиламиноалкила, N-ариламиноалкила, N-аралкиламиноалкила, N-алкил-N-аралкиламиноалкила, N-алкил-N-ариламиноалкила, арилокси, аралкокси, арилтио, аралкилтио, алкилсульфинила, алкилсульфонила, аминосульфонила, алкиламиносульфонила, N-ариламиносульфонила, арилсульфонила, N-алкил-N-ариламиносульфонила; или их фармацевтически приемлемую соль.13. The application indicated in paragraph 12, in which the selective inhibitor SOH-2 is a compound of formula I
where a represents a Deputy, selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;
R 1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl, or aryl, and R 1 is optionally substituted in substitutable position by one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxy alkyl, haloalkoxy, , amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halogen, alkoxy and alkylthio;
R 2 is methyl or amino; and
R 3 is a radical selected from hydrido, halogen, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, pendant, peptide, peptide, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkyl, alkoxy , hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aralkoxyalkyl, alkaroxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxyalkyl, liqoxycarboxylic, alkoxycarbonylalkyl, aralkoxyalkyl, alkoxycarbonyl, aralkoxycarbonyl, arylcarbonyl alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkilaminokarbonilalkila, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N- arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-ps-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulphinyl, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, anhydropylacetate arylaminosulfonyl; or a pharmaceutically acceptable salt thereof.
R1 выбран из 5- или 6-членного гетероциклила, низшего циклоалкила, низшего циклоалкенила и арила, выбранного из фенила, бифенила и нафтила, причем R1 является необязательно замещенным в замещаемом положении одним или несколькими радикалами, выбранными из низшего алкила, низшего галогеналкила, циано, карбоксила, низшего алкоксикарбонила, гидроксила, низшего гидроксиалкила, низшего галогеналкокси, амино, низшего алкиламино, фениламино, низшего алкоксиалкила, низшего алкилсульфинила, галогена, низшего алкокси и низшего алкилтио;
R2 представляет метил или амино и
R3 представляет радикал, выбранный из гидридо, оксо, циано, карбоксила, низшего алкоксикарбонила, низшего карбоксиалкила, низшего цианоалкила, галогена, низшего алкила, низшего алкилокси, низшего циклоалкила, фенила, низшего галогеналкила, 5- или 6-членного гетероциклила, низшего гидроксиалкила, низшего аралкила, ацила, фенилкарбонила, низшего алкоксиалкила, 5- или 6-членного гетероарилокси, аминокарбонила, низшего алкиламинокарбонила, низшего алкиламино, низшего аминоалкила, низшего алкиламиноалкила, фенилокси и низшего аралкокси;
или их фармацевтически приемлемую соль.14. The use according to claim 13, wherein A is selected from a 5- or 6-membered partially unsaturated heterocyclyl, a 5- or 6-membered unsaturated heterocyclyl, a 9-or 10-membered unsaturated condensed heterocyclyl, lower cycloalkenyl and phenyl;
R 1 is selected from 5 or 6 membered heterocyclyl, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, and R 1 is optionally substituted in substitutable position by one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, lower alkoxyalkyl, lower alkylsulfinyl, halogen, lower alkoxy, and lower alkylthio;
R 2 is methyl or amino and
R 3 is a radical selected from hydrido, oxo, cyano, carboxyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, halogen, lower alkyl, lower alkyloxy, lower cycloalkyl, phenyl, lower halogenoalkyl, 5- or 6-membered heterocyclyl, lower cycloalkyl, 5-or 6-membered heterocyclyl, lower or more halo-cycloalkyl, phenyl, lower haloalkyl, 5- or 6-membered , lower aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl, 5- or 6-membered heteroaryloxy, aminocarbonyl, lower alkylaminocarbonyl, lower alkylamino, lower aminoalkyl, lower alkylaminoalkyl, phenyloxy and lower aralkoxy;
or a pharmaceutically acceptable salt thereof.
R1 выбран из пиридила, необязательно замещенного в замещаемом положении одним или несколькими метильными радикалами, и фенила, необязательно замещенного в замещаемом положении одним или несколькими радикалами, выбранными из метила, этила, изопропила, бутила, трет-бутила, изобутила, пентила, гексила, фторметила, дифторметила, трифторметила, циано, карбоксила, метоксикарбонила, этоксикарбонила, гидроксила, гидроксиметила, трифторметокси, амино, N-метиламино, N,N-диметиламино, N-этиламино, N,N-дипропиламино, N-бутиламино, N-метил-N-этиламино, фениламино, метоксиметила, метилсульфинила, фтора, хлора, брома, метокси, этокси, пропокси, н-бутокси, пентокси и метилтио;
R2 представляет метил или амино и
R3 представляет радикал, выбранный из гидридо, оксо, циано, карбоксила, метоксикарбонила, этоксикарбонила, карбоксипропила, карбоксиметила, карбоксиэтила, цианометила, фтора, хлора, брома, метила, этила, изопропила, бутила, трет-бутила, изобутила, пентила, гексила, дифторметила, трифторметила, пентафторэтила, гептафторпропила, дифторэтила, дифторпропила, метокси, этокси, пропокси, н-бутокси, пентокси, циклогексила, фенила, пиридила, тиенила, тиазолила, оксазолила, фурила, пиразинила, гидроксилметила, гидроксилпропила, бензила, формила, фенилкарбонила, метоксиметила, фурилметилокси, аминокарбонила, N-метиламинокарбонила, N,N-диметиламинокарбонила, N,N-диметиламино, N-этиламино, N,N-дипропиламино, N-бутиламино, N-метил-N-этиламино, аминометила, N,N-диметиламинометила, N-метил-N-этиламинометила, бензилокси и фенилокси;
или их фармацевтически приемлемую соль.15. The use according to claim 14, wherein A is selected from oxazolyl, isoxazolyl, furyl, thienyl, dihydrofuryl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, benzofuryl, cyclopentenyl, cyclopentadienyl, phenyl and pyridyl;
R 1 is selected from pyridyl, optionally substituted in a substitutable position by one or more methyl radicals, and phenyl, optionally substituted in a substitutable position by one or more radicals selected from methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, hydroxyl, hydroxymethyl, trifluoromethoxy, amino, N-methylamino, N, N-dimethylamino, N-ethylamino, N, N-dipropylamino, N-butylamino, N N-ethylamino, phenyl amino, methoxymethyl, methylsulfinyl, fluorine, chlorine, bromine, methoxy, ethoxy, propoxy, n-butoxy, pentoxy and methylthio;
R 2 is methyl or amino and
R 3 is a radical selected from hydrido, oxo, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, carboxypropyl, carboxymethyl, carboxyethyl, cyanomethyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl diferometil rbonyl, methoxymethyl, furylmethyloxy, aminocarbonyl, N-methylaminocarbonyl, N, N-dimethylaminocarbonyl, N, N-dimethylamino, N-ethylamino, N, N-dipropylamino, N-butylamino, N-methyl-N-ethylamino, aminomethyl, N, N-dimethylaminomethyl, N-methyl-N-ethylaminomethyl, benzyloxy, and phenyloxy;
or a pharmaceutically acceptable salt thereof.
5-(4-фторфенил)-1-[4-(метилсульфонил)фенил]-3-(трифторметил)пиразола;
4-(4-фторфенил)-5-[4-(метилсульфонил)фенил] -1-фенил-3-(трифторметил) пиразола;
4-(5-(4-хлорфенил)-3-(4-метоксифенил)-1Н-пиразол-1-ил)бензолсульфонамида;
4-(3,5-бис(4-метилфенил)-1Н-пиразол-1-ил)бензолсульфонамида;
4-(5-(4-хлорфенил)-3-фенил-1Н-пиразол-1-ил)бензолсульфонамида;
4-(3,5-бис(4-метоксифенил)-1Н-пиразол-1-ил)бензолсульфонамида;
4-(5-(4-хлорфенил)-3-(4-метилфенил)-1Н-пиразол-1-ил)бензолсульфонамида;
4-(5-(4-хлорфенил)-3-(4-нитрофенил)-1Н-пиразол-1-ил)бензолсульфонамида;
4-(5-(4-хлорфенил)-3-(5-хлор-2-тиенил)-1Н-пиразол-1-ил)бензолсульфонамида;
4-(4-хлор-3,5-дифенил-1Н-пиразол-1-ил)бензолсульфонамида;
4-[5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-фенил-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-фторфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[5-(4-хлорфенил)-3-(дифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метилфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[4-хлор-5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-(4-метилфенил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-фенил-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-(4-метоксифенил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[3-циано-5-(4-фторфенил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[3-(дифторметил)-5-(3-фтор-4-метоксифенил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(3-фтор-4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида;
4-[4-хлор-5-фенил-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-хлорфенил)-3-(гидроксиметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-(N, N-диметиламино) фенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
5-(4-фторфенил)-6-[4-(метилсульфонил)фенил]спиро[2.4]гепт-5-ена;
4-[6-(4-фторфенил)спиро[2.4]гепт-5-ен-5-ил]бензолсульфонамида;
6-(4-фторфенил)-7-[4-(метилсульфонил)фенил]спиро[3.4]окт-6-ена;
5-(3-хлор-4-метоксифенил)-6-[4-(метилсульфонил)фенил] спиро[2.4]гепт-5-ена;
4-[6-(3-хлор-4-метоксифенил)спиро[2.4]гепт-5-ен-5-ил]бензолсульфонамида;
5-(3,5-дихлор-4-метоксифенил)-6-[4-(метилсульфонил)фенил] спиро[2.4] гепт-5-ена;
5-(3-хлор-4-фторфенил)-6-[4-(метилсульфонил) фенил] спиро [2.4]гепт-5-ена;
4-[6-(3,4-дихлорфенил)спиро[2.4]гепт-5-ен-5-ил]бензолсульфонамида;
2-(3-хлор-4-фторфенил)-4-(4-фторфенил)-5-(4-метилсульфонилфенил)тиазола;
2-(2-хлорфенил)-4-(4-фторфенил)-5-(4-метилсульфонилфенил)тиазола;
5-(4-фторфенил)-4-(4-метилсульфонилфенил)-2-метилтиазола;
4-(4-фторфенил)-5-(4-метилсульфонилфенил)-2-трифторметилтиазола;
4-(4-фторфенил)-5-(4-метилсульфонилфенил)-2-(2-тиенил) тиазола;
4-(4-фторфенил)-5-(4-метилсульфонилфенил)-2-бензиламинотиазола;
4-(4-фторфенил)-5-(4-метилсульфонилфенил)-2-(1-пропиламино)тиазола;
2-[(3,5-дихлорфенокси)метил)-4-(4-фторфенил)-5-[4-(метилсульфонил)фенил)тиазола;
5-(4-фторфенил)-4-(4-метилсульфонилфенил)-2-трифторметилтиазола;
1-метилсульфонил-4-[1,1-диметил-4-(4-фторфенил)циклопента-2,4-диен-3-ил] бензола;
4-[4-(4-фторфенил]-1,1-диметилциклопента-2,4-диен-3-ил]бензолсульфонамида;
5-[4-фторфенил)-6-[4-(метилсульфонил)фенил]спиро[2.4]гепта-4,6-диена;
4-[6-(4-фторфенил)спиро[2.4]гепта-4,6-диен-5-ил]бензолсульфонамида;
6-(4-фторфенил)-2-метокси-5-[4-(метилсульфонил)фенил] пиридин-3-карбонитрила;
2-бром-6-(4-фторфенил)-5-[4-(метилсульфонил)фенил] пиридин-3-карбонитрила;
6-(4-фторфенил)-5-[4-(метилсульфонил)фенил] -2-фенилпиридин-3-карбонитрила;
4-[2-(4-метилпиридин-2-ил)-4-(трифторметил)-1H-имидазол-1-ил]бензолсульфонамида;
4-[2-(5-метилпиридин-3-ил)-4-(трифторметил)-1H-имидазол-1-ил]бензолсульфонамида;
4-[2-(2-метилпиридин-3-ил)-4-(трифторметил)-1H-имидазол-1-ил]бензолсульфонамида;
3-[1-[4-(метилсульфонил)фенил]-4-(трифторметил)-1H-имидазол-2-ил]пиридина;
2-[1-[4-(метилсульфонил) фенил]-4-(трифторметил)-1H-имидазол-2-ил]пиридина;
2-метил-4-[1-[4-(метилсульфонил)фенил] -4-(трифторметил)-1Н-имидазол-2-ил]пиридина;
2-метил-6-[1-[4-(метилсульфонил)фенил] -4-(трифторметил)-1Н-имидазол-2-ил]пиридина;
4-[2-(6-метилпиридин-3-ил)-4-(трифторметил)-1H-имидазол-1-ил] бензолсульфонамида;
2-(3,4-дифторфенил)-1-[4-(метилсульфонил)фенил] -4-(трифторметил)-1H-имидазола;
4-[2-(4-метилфенил)-4-(трифторметил)-1Н-имидазол-1-ил] бензолсульфонамида;
2-(4-фторфенил)-1-[4-(метилсульфонил)фенил]-4-метил-1Н-имидазола;
2-(4-фторфенил)-1-[4-(метилсульфонил)фенил]-4-фенил-1Н-имидазола;
2-(4-фторфенил)-4-(4-фторфенил)-1-[4-(метилсульфонил)фенил] -1Н-имидазола;
2-(3-фтор-4-метоксифенил)-1-[4-(метилсульфонил)фенил]-4-(трифторметил)-1Н-имидазола;
1-[4-(метилсульфонил)фенил]-2-фенил-4-трифторметил-1Н-имидазола;
2-(4-метилфенил)-1-[4-(метилсульфонил)фенил] -4-трифторметил-1H-имидазола;
4-[2-(3-хлор-4-метилфенил)-4-(трифторметил)-1H-имидазол-1-ил]бензолсульфонамида;
2-(3-фтор-5-метилфенил)-1-[4-(метилсульфонил)фенил] -4-(трифторметил)-1H-имидазола;
4-[2-(3-фтор-5-метилфенил)-4-(трифторметил)-1H-имидазол-1-ил] бензолсульфонамида;
2-(3-метилфенил)-1-[4-(метилсульфонил)фенил] -4-трифторметил-1H-имидазола;
4-[2-(3-метилфенил)-4-трифторметил-1Н-имидазол-1-ил]бензолсульфонамида;
1-[4-(метилсульфонил)фенил]-2-(3-хлорфенил)-4-трифторметил-1Н-имидазола;
4-[2-(3-хлорфенил)-4-трифторметил-1Н-имидазол-1-ил]бензолсульфонамида;
4-[2-фенил-4-трифторметил-1Н-имидазол-1ил]бензолсульфонамида;
4-[2-(4-метокси-3-хлорфенил)-4-трифторметил-1Н-имидазол-1-ил]бензолсульфонамида;
1-аллил-4-(4-фторфенил)-3-[4-(метилсульфонил)фенил] -5-(трифторметил)-1Н-пиразола;
4-[1-этил-4-(4-фторфенил)-5-(трифторметил)-1H-пиразол-3-ил] бензолсульфонамида;
N-фенил-[4-(4-фторфенил)-3-[4-(метилсульфонил)фенил] -5-(трифторметил)-1Н-пиразол-1-ил]ацетамид;
этил [4-(4-фторфенил)-3-[4-(метилсульфонил)фенил]-5-(трифторметил)-1Н-пиразол-1-ил]ацетата;
4-(4-фторфенил)-3-[4-(метилсульфонил)фенил]-1-(2-фенилэтил)-1Н-пиразола;
4- ( 4-фторфенил) -3-[4- (метилсульфонил) фенил]-1- (2-фенилэтил)-5-(трифторметил)пиразола;
1-этил-4-(4-фторфенил)-3-[4- (метилсульфонил)фенил] -5-(трифторметил)-1H-пиразола;
5-(4-фторфенил)-4-(4-метилсульфонилфенил)-2-трифторметил-1Н-имидазола;
4-[4- (метилсульфонил)фенил] -5-(2-тиофенил)-2-(трифторметил)-1H-имидазола;
5-(4-фторфенил)-2-метокси-4-[4-(метилсульфонил)фенил]-6-(трифторметил)пиридина;
2-этокси-5-(4-фторфенил)-4-[4-(метилсульфонил)фенил]-6-(трифторметил)пиридина;
5-(4-фторфенил)-4-[4-(метилсульфонил)фенил] -2-(2-пропинилокси)-6-(трифторметил)пиридина;
2-бром-5-(4-фторфенил)-4-[4-(метилсульфонил)фенил]-6-(трифторметил)пиридина;
4-[2-(3-хлор-4-метоксифенил)-4,5-(дифторфенил)бензолсульфонамида;
1-(4-фторфенил)-2-[4-(метилсульфонил)фенил]бензола;
5-дифторфенил-4-(4-метилсульфонилфенил)-3-фенилизоксазола;
4-[3-этил-5-фенилизоксазол-4-ил]бензолсульфонамида;
4-[5-дифторметил-3-фенилизоксазол-4-ил]бензолсульфонамида;
4-[5-гидроксиметил-3-фенилизоксазол-4-ил]бензолсульфонамида;
4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида;
1-[2-(4-фторфенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
1-[2-(4-фтор-2-метилфенил)циклопентен-1-ил]-4-(метилсульфонил) бензола;
1-[2-(4-хлорфенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
1-[2-(2,4-дихлорфенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
1-[2-(4-трифторметилфенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
1-[2-(4-метилтиофенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
1-[2-(4-фторфенил)-4,4-диметилциклопентен-1-ил]-4-(метилсульфонил)бензола;
4-[2-(4-фторфенил)-4,4-диметилциклопентен-1-ил]бензолсульфонамида;
1-[2-(4-хлорфенил)-4,4-диметилциклопентен-1-ил]-4-(метилсульфонил)бензола;
4-[2-(4-хлорфенил)-4,4-диметилциклопентен-1-ил]бензолсульфонамида;
4-[2-(4-фторфенил)циклопентен-1-ил]бензолсульфонамида;
4-[2-(4-хлорфенил)циклопентен-1-ил]бензолсульфонамида;
1-[2-(4-метоксифенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
1-[2-(2,3-дифторфенил) циклопентен-1-ил]-4-(метилсульфонил) бензола;
4-[2-(3-фтор-4-метоксифенил)циклопентен-1-ил]бензолсульфонамида;
1-[2-(3-хлор-4-метоксифенил)циклопентен-1-ил]-4-(метилсульфонил)бензола;
4-[2-(3-хлор-4-фторфенил)циклопентен-1-ил]бензолсульфонамида;
4-[2-(2-метилпиридин-5-ил)циклопентен-1-ил]бензолсульфонамида;
этил 2-[4-(4-фторфенил)-5-[4-(метилсульфонил)фенил]оксазол-2-ил]-2-бензилацетата;
2-[4-(4-фторфенил)-5-[4-(метилсульфонил)фенил] оксазол-2-ил] уксусной кислоты;
2-(трет-бутил)-4-(4-фторфенил)-5-[4-(метилсульфонил)фенил]оксазола;
4-(4-фторфенил)-5-[4-(метилсульфонил)фенил]-2-фенилоксазола;
4-(4-фторфенил)-2-метил-5-[4-(метилсульфонил)фенил]оксазола и
4-[5-(3-фтор-4-метоксифенил)-2-трифторметил-4-оксазолил]бензолсульфонамида.16. The application indicated in paragraph 15, in which the compound is selected from the group of compounds and their pharmaceutically acceptable salts, consisting of
5- (4-fluorophenyl) -1- [4- (methylsulfonyl) phenyl] -3- (trifluoromethyl) pyrazole;
4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] -1-phenyl-3- (trifluoromethyl) pyrazole;
4- (5- (4-chlorophenyl) -3- (4-methoxyphenyl) -1H-pyrazol-1-yl) benzenesulfonamide;
4- (3,5-bis (4-methylphenyl) -1H-pyrazol-1-yl) benzenesulfonamide;
4- (5- (4-chlorophenyl) -3-phenyl-1H-pyrazol-1-yl) benzenesulfonamide;
4- (3,5-bis (4-methoxyphenyl) -1H-pyrazol-1-yl) benzenesulfonamide;
4- (5- (4-chlorophenyl) -3- (4-methylphenyl) -1H-pyrazole-1-yl) benzenesulfonamide;
4- (5- (4-chlorophenyl) -3- (4-nitrophenyl) -1H-pyrazol-1-yl) benzenesulfonamide;
4- (5- (4-chlorophenyl) -3- (5-chloro-2-thienyl) -1H-pyrazol-1-yl) benzenesulfonamide;
4- (4-chloro-3,5-diphenyl-1H-pyrazol-1-yl) benzenesulfonamide;
4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5-phenyl-3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [5- (4-fluorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-chlorophenyl) -3- (difluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [4-chloro-5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (4-methylphenyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5-phenyl-1H-pyrazol-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (4-methoxyphenyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [3-cyano-5- (4-fluorophenyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [3- (difluoromethyl) -5- (3-fluoro-4-methoxyphenyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [5- (3-fluoro-4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
4- [4-chloro-5-phenyl-1H-pyrazol-1-yl] benzenesulfonamide;
4- [5- (4-chlorophenyl) -3- (hydroxymethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4- (N, N-dimethylamino) phenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
5- (4-fluorophenyl) -6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene;
4- [6- (4-fluorophenyl) spiro [2.4] hept-5-en-5-yl] benzenesulfonamide;
6- (4-fluorophenyl) -7- [4- (methylsulfonyl) phenyl] spiro [3.4] oct-6-ene;
5- (3-chloro-4-methoxyphenyl) -6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene;
4- [6- (3-chloro-4-methoxyphenyl) spiro [2.4] hept-5-en-5-yl] benzenesulfonamide;
5- (3,5-dichloro-4-methoxyphenyl) -6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene;
5- (3-chloro-4-fluorophenyl) -6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene;
4- [6- (3,4-dichlorophenyl) spiro [2.4] hept-5-ene-5-yl] benzenesulfonamide;
2- (3-chloro-4-fluorophenyl) -4- (4-fluorophenyl) -5- (4-methylsulfonylphenyl) thiazole;
2- (2-chlorophenyl) -4- (4-fluorophenyl) -5- (4-methylsulfonylphenyl) thiazole;
5- (4-fluorophenyl) -4- (4-methylsulfonylphenyl) -2-methylthiazole;
4- (4-fluorophenyl) -5- (4-methylsulfonylphenyl) -2-trifluoromethylthiazole;
4- (4-fluorophenyl) -5- (4-methylsulfonylphenyl) -2- (2-thienyl) thiazole;
4- (4-fluorophenyl) -5- (4-methylsulfonylphenyl) -2-benzylaminothiazole;
4- (4-fluorophenyl) -5- (4-methylsulfonylphenyl) -2- (1-propylamino) thiazole;
2 - [(3,5-dichlorophenoxy) methyl) -4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl) thiazole;
5- (4-fluorophenyl) -4- (4-methylsulfonylphenyl) -2-trifluoromethylthiazole;
1-methylsulfonyl-4- [1,1-dimethyl-4- (4-fluorophenyl) cyclopent-2,4-dien-3-yl] benzene;
4- [4- (4-fluorophenyl] -1,1-dimethylcyclopenta-2,4-diene-3-yl] benzenesulfonamide;
5- [4-fluorophenyl) -6- [4- (methylsulfonyl) phenyl] spiro [2.4] hepta-4,6-diene;
4- [6- (4-fluorophenyl) spiro [2.4] hepta-4,6-diene-5-yl] benzenesulfonamide;
6- (4-fluorophenyl) -2-methoxy-5- [4- (methylsulfonyl) phenyl] pyridine-3-carbonitrile;
2-bromo-6- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] pyridine-3-carbonitrile;
6- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] -2-phenylpyridin-3-carbonitrile;
4- [2- (4-methylpyridin-2-yl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
4- [2- (5-methylpyridin-3-yl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
4- [2- (2-methylpyridin-3-yl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
3- [1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazol-2-yl] pyridine;
2- [1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazol-2-yl] pyridine;
2-methyl-4- [1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazol-2-yl] pyridine;
2-methyl-6- [1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazol-2-yl] pyridine;
4- [2- (6-methylpyridin-3-yl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
2- (3,4-difluorophenyl) -1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazole;
4- [2- (4-methylphenyl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
2- (4-fluorophenyl) -1- [4- (methylsulfonyl) phenyl] -4-methyl-1H-imidazole;
2- (4-fluorophenyl) -1- [4- (methylsulfonyl) phenyl] -4-phenyl-1H-imidazole;
2- (4-fluorophenyl) -4- (4-fluorophenyl) -1- [4- (methylsulfonyl) phenyl] -1H-imidazole;
2- (3-fluoro-4-methoxyphenyl) -1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazole;
1- [4- (methylsulfonyl) phenyl] -2-phenyl-4-trifluoromethyl-1H-imidazole;
2- (4-methylphenyl) -1- [4- (methylsulfonyl) phenyl] -4-trifluoromethyl-1H-imidazole;
4- [2- (3-chloro-4-methylphenyl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
2- (3-fluoro-5-methylphenyl) -1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl) -1H-imidazole;
4- [2- (3-fluoro-5-methylphenyl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
2- (3-methylphenyl) -1- [4- (methylsulfonyl) phenyl] -4-trifluoromethyl-1H-imidazole;
4- [2- (3-methylphenyl) -4-trifluoromethyl-1H-imidazol-1-yl] benzenesulfonamide;
1- [4- (methylsulfonyl) phenyl] -2- (3-chlorophenyl) -4-trifluoromethyl-1H-imidazole;
4- [2- (3-chlorophenyl) -4-trifluoromethyl-1H-imidazol-1-yl] benzenesulfonamide;
4- [2-phenyl-4-trifluoromethyl-1H-imidazol-1yl] benzenesulfonamide;
4- [2- (4-methoxy-3-chlorophenyl) -4-trifluoromethyl-1H-imidazol-1-yl] benzenesulfonamide;
1-allyl-4- (4-fluorophenyl) -3- [4- (methylsulfonyl) phenyl] -5- (trifluoromethyl) -1H-pyrazole;
4- [1-ethyl-4- (4-fluorophenyl) -5- (trifluoromethyl) -1H-pyrazol-3-yl] benzenesulfonamide;
N-phenyl- [4- (4-fluorophenyl) -3- [4- (methylsulfonyl) phenyl] -5- (trifluoromethyl) -1H-pyrazol-1-yl] acetamide;
ethyl [4- (4-fluorophenyl) -3- [4- (methylsulfonyl) phenyl] -5- (trifluoromethyl) -1H-pyrazol-1-yl] acetate;
4- (4-fluorophenyl) -3- [4- (methylsulfonyl) phenyl] -1- (2-phenylethyl) -1H-pyrazole;
4- (4-fluorophenyl) -3- [4- (methylsulfonyl) phenyl] -1- (2-phenylethyl) -5- (trifluoromethyl) pyrazole;
1-ethyl-4- (4-fluorophenyl) -3- [4- (methylsulfonyl) phenyl] -5- (trifluoromethyl) -1H-pyrazole;
5- (4-fluorophenyl) -4- (4-methylsulfonylphenyl) -2-trifluoromethyl-1H-imidazole;
4- [4- (methylsulfonyl) phenyl] -5- (2-thiophenyl) -2- (trifluoromethyl) -1H-imidazole;
5- (4-fluorophenyl) -2-methoxy-4- [4- (methylsulfonyl) phenyl] -6- (trifluoromethyl) pyridine;
2-ethoxy-5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -6- (trifluoromethyl) pyridine;
5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -2- (2-propynyloxy) -6- (trifluoromethyl) pyridine;
2-bromo-5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -6- (trifluoromethyl) pyridine;
4- [2- (3-chloro-4-methoxyphenyl) -4,5- (difluorophenyl) benzenesulfonamide;
1- (4-fluorophenyl) -2- [4- (methylsulfonyl) phenyl] benzene;
5-difluorophenyl-4- (4-methylsulfonylphenyl) -3-phenylisoxazole;
4- [3-ethyl-5-phenylisoxazol-4-yl] benzenesulfonamide;
4- [5-difluoromethyl-3-phenylisoxazol-4-yl] benzenesulfonamide;
4- [5-hydroxymethyl-3-phenylisoxazol-4-yl] benzenesulfonamide;
4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide;
1- [2- (4-fluorophenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (4-fluoro-2-methylphenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (4-chlorophenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (2,4-dichlorophenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (4-trifluoromethylphenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (4-methylthiophenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (4-fluorophenyl) -4,4-dimethylcyclopenten-1-yl] -4- (methylsulfonyl) benzene;
4- [2- (4-fluorophenyl) -4,4-dimethylcyclopenten-1-yl] benzenesulfonamide;
1- [2- (4-chlorophenyl) -4,4-dimethylcyclopenten-1-yl] -4- (methylsulfonyl) benzene;
4- [2- (4-chlorophenyl) -4,4-dimethylcyclopenten-1-yl] benzenesulfonamide;
4- [2- (4-fluorophenyl) cyclopenten-1-yl] benzenesulfonamide;
4- [2- (4-chlorophenyl) cyclopenten-1-yl] benzenesulfonamide;
1- [2- (4-methoxyphenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
1- [2- (2,3-difluorophenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
4- [2- (3-fluoro-4-methoxyphenyl) cyclopenten-1-yl] benzenesulfonamide;
1- [2- (3-chloro-4-methoxyphenyl) cyclopenten-1-yl] -4- (methylsulfonyl) benzene;
4- [2- (3-chloro-4-fluorophenyl) cyclopenten-1-yl] benzenesulfonamide;
4- [2- (2-methylpyridin-5-yl) cyclopenten-1-yl] benzenesulfonamide;
ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] -2-benzyl acetate;
2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] acetic acid;
2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazole;
4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] -2-phenyloxazole;
4- (4-fluorophenyl) -2-methyl-5- [4- (methylsulfonyl) phenyl] oxazole and
4- [5- (3-fluoro-4-methoxyphenyl) -2-trifluoromethyl-4-oxazolyl] benzenesulfonamide.
4-[5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(4-метилфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
4-[5-(3-фтор-4-метоксифенил)-3-(дифторметил)-1Н-пиразол-1-ил]бензолсульфонамида;
3-[1-[4-(метилсульфонил)фенил]-4-трифторметил-1Н-имидазол-2-ил]пиридина;
2-метил-5-[1-[4-(метилсульфонил)фенил] -4-трифторметил-1Н-имидазол-2-ил] пиридина;
4-[2-(5-метилпиридин-3-ил)-4-(трифторметил)-1H-имидазол-1-ил]бензолсульфонамида;
4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида;
4-[5-гидроксиметил-3-фенилизоксазол-4-ил]бензолсульфонамида;
[2-трифторметил-5-(3,4-дифторфенил)-4-оксазолил]бензолсульфонамида;
4-[2-метил-4-фенил-5-оксазолил]бензолсульфонамида и
4-[5-(3-фтор-4-метоксифенил-2-трифторметил)-4-оксазолил]бензолсульфонамида.17. The application of clause 16, in which the compound is selected from the group of compounds and their pharmaceutically acceptable salts, consisting of
4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazole-1-yl] benzenesulfonamide;
4- [5- (3-fluoro-4-methoxyphenyl) -3- (difluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide;
3- [1- [4- (methylsulfonyl) phenyl] -4-trifluoromethyl-1H-imidazol-2-yl] pyridine;
2-methyl-5- [1- [4- (methylsulfonyl) phenyl] -4-trifluoromethyl-1H-imidazol-2-yl] pyridine;
4- [2- (5-methylpyridin-3-yl) -4- (trifluoromethyl) -1H-imidazol-1-yl] benzenesulfonamide;
4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide;
4- [5-hydroxymethyl-3-phenylisoxazol-4-yl] benzenesulfonamide;
[2-trifluoromethyl-5- (3,4-difluorophenyl) -4-oxazolyl] benzenesulfonamide;
4- [2-methyl-4-phenyl-5-oxazolyl] benzenesulfonamide and
4- [5- (3-fluoro-4-methoxyphenyl-2-trifluoromethyl) -4-oxazolyl] benzenesulfonamide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2849496P | 1996-10-15 | 1996-10-15 | |
US60/028,494 | 1996-10-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99110192A true RU99110192A (en) | 2001-03-27 |
RU2239429C2 RU2239429C2 (en) | 2004-11-10 |
Family
ID=21843754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99110192/15A RU2239429C2 (en) | 1996-10-15 | 1997-10-14 | Method for applying cyclooxygenase-2 inhibitor for treatment and prophylaxis of neoplasia |
Country Status (25)
Country | Link |
---|---|
EP (3) | EP1479385B1 (en) |
JP (1) | JP2001503395A (en) |
KR (1) | KR20000049138A (en) |
CN (2) | CN100558356C (en) |
AT (2) | ATE399547T1 (en) |
AU (1) | AU742645B2 (en) |
BR (1) | BR9712314A (en) |
CA (1) | CA2267186C (en) |
CZ (1) | CZ298022B6 (en) |
DE (2) | DE69738815D1 (en) |
DK (2) | DK0932402T3 (en) |
ES (2) | ES2224222T3 (en) |
HK (1) | HK1025518A1 (en) |
HU (1) | HU227564B1 (en) |
IL (3) | IL154501A0 (en) |
NO (1) | NO326822B1 (en) |
NZ (3) | NZ334921A (en) |
PT (2) | PT932402E (en) |
RO (1) | RO120172B1 (en) |
RU (1) | RU2239429C2 (en) |
SK (1) | SK284788B6 (en) |
TR (1) | TR199900827T2 (en) |
TW (1) | TWI235060B (en) |
UA (1) | UA67732C2 (en) |
WO (1) | WO1998016227A1 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2223154A1 (en) | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US6727238B2 (en) | 1998-06-11 | 2004-04-27 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
JP2002533416A (en) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | Methods of using cyclooxygenase-2 inhibitors and one or more antineoplastic agents as combination therapy in the treatment of neoplasia |
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
ATE425749T1 (en) * | 1999-01-27 | 2009-04-15 | Cornell Res Foundation Inc | TREATMENT OF HER-2/NEW OVEREXPRESSION-ASSOCIATED CANCER |
NZ515711A (en) * | 1999-06-24 | 2004-01-30 | Pharmacia Corp | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation |
CA2380078C (en) * | 1999-07-29 | 2008-05-06 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides |
MXPA02005106A (en) | 1999-11-22 | 2002-11-07 | Smithkline Beecham Plc | Novel compounds. |
AU3653301A (en) * | 2000-01-28 | 2001-08-07 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
US20020009421A1 (en) * | 2000-06-01 | 2002-01-24 | Wilder Karol J. | Therapy following skin injury from exposure to ultraviolet radiation |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
EP1318992B1 (en) | 2000-09-21 | 2005-07-27 | Smithkline Beecham Plc | Imidazole derivatives as raf kinase inhibitors |
WO2002039958A2 (en) | 2000-11-03 | 2002-05-23 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
EP1390026B1 (en) * | 2001-05-03 | 2010-05-05 | Cornell Research Foundation, Inc. | Treatment of hpv caused diseases |
GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0119477D0 (en) | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
PT1441714E (en) * | 2001-10-25 | 2008-03-10 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
FR2835433B1 (en) * | 2002-02-01 | 2006-02-17 | Richard Lab M | USE OF 1- (4-CHLOROBENZOYL) -5-METHHOXY-2-METHYL-1H-INDOLE-3ACETIC 4- (ACETYLAMINO) PHENYL ESTER FOR THE PRODUCTION OF A MEDICAMENT FOR INHIBITING COX2 EXCLUSIVELY |
US7232821B2 (en) | 2002-04-08 | 2007-06-19 | Glaxo Group Limited | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives |
AU2003258630A1 (en) | 2002-08-19 | 2004-03-11 | Glaxo Group Limited | Pyrimidine derivatives as selective cox-2 inhibitors |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
KR100484525B1 (en) * | 2002-10-15 | 2005-04-20 | 씨제이 주식회사 | Isothiazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
AR042206A1 (en) | 2002-11-26 | 2005-06-15 | Novartis Ag | PHENYLACETIC ACIDS AND DERIVATIVES |
EA009919B1 (en) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Isoxazole compounds |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
BRPI0607688A2 (en) | 2005-02-17 | 2009-09-22 | Synta Pharmaceuticals Corp | method for inhibiting tubulin polymerization in a cell; method for treating or preventing a proliferative disorder in an individual; method of blocking, occluding or otherwise disrupting blood flow to the neovasculature; compound; pharmaceutical composition and use of said method and compound |
JP5197355B2 (en) * | 2005-03-08 | 2013-05-15 | 三井農林株式会社 | Combinations and methods of polyphenols and coxibs |
JPWO2010007943A1 (en) * | 2008-07-17 | 2012-01-05 | 旭化成ファーマ株式会社 | Nitrogen-containing heterocyclic compounds |
JP2012500630A (en) * | 2008-08-22 | 2012-01-12 | ノバルティス アーゲー | Use of COX-2 inhibitors to treat COX-2 dependent disorders in patients who do not have an HLA allele associated with hepatotoxicity |
EP3313399A4 (en) | 2015-06-29 | 2019-07-24 | NantBio, Inc. | Compositions and methods of rit1 inhibition |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
JP3155552B2 (en) | 1991-07-19 | 2001-04-09 | モンサント カンパニー | Manganese complexes of nitrogen-containing macrocyclic ligands as effective catalysts for the asymmetric change of superoxide |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
CA2152792C (en) | 1993-01-15 | 2000-02-15 | Stephen R. Bertenshaw | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
WO1994026731A1 (en) | 1993-05-13 | 1994-11-24 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5475018A (en) | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
RU2139281C1 (en) * | 1993-11-30 | 1999-10-10 | Джи Ди Сирл энд Компани | Pyrazolyl-substituted benzenesulfoneamide or its pharmaceutically acceptable salt, method of treatment of patients with inflammation or inflammation-associated diseases |
US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
JPH10504542A (en) | 1994-07-27 | 1998-05-06 | ジー.ディー.サール アンド カンパニー | Substituted thiazole compounds for treating inflammation |
US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5739166A (en) | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
US5596008A (en) | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5686470A (en) | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
CA2212836C (en) | 1995-02-13 | 2003-08-12 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
CA2223154A1 (en) * | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
WO1997008174A1 (en) | 1995-08-31 | 1997-03-06 | Smithkline Beecham Corporation | Interleukin converting enzyme and apoptosis |
ATE225343T1 (en) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | MATRIX METALLOPROTEASE INHIBITORS |
-
1997
- 1997-10-14 UA UA99052704A patent/UA67732C2/en unknown
- 1997-10-14 CZ CZ0117199A patent/CZ298022B6/en not_active IP Right Cessation
- 1997-10-14 NZ NZ334921A patent/NZ334921A/en not_active IP Right Cessation
- 1997-10-14 HU HU9904221A patent/HU227564B1/en not_active IP Right Cessation
- 1997-10-14 SK SK462-99A patent/SK284788B6/en not_active IP Right Cessation
- 1997-10-14 NZ NZ506515A patent/NZ506515A/en not_active IP Right Cessation
- 1997-10-14 DE DE69738815T patent/DE69738815D1/en not_active Expired - Lifetime
- 1997-10-14 TW TW090122228A patent/TWI235060B/en not_active IP Right Cessation
- 1997-10-14 PT PT97911746T patent/PT932402E/en unknown
- 1997-10-14 KR KR1019990703225A patent/KR20000049138A/en not_active Application Discontinuation
- 1997-10-14 ES ES97911746T patent/ES2224222T3/en not_active Expired - Lifetime
- 1997-10-14 RO RO99-00418A patent/RO120172B1/en unknown
- 1997-10-14 EP EP04011516A patent/EP1479385B1/en not_active Expired - Lifetime
- 1997-10-14 AT AT04011516T patent/ATE399547T1/en active
- 1997-10-14 WO PCT/US1997/018670 patent/WO1998016227A1/en active IP Right Grant
- 1997-10-14 CN CNB2005100062282A patent/CN100558356C/en not_active Expired - Fee Related
- 1997-10-14 DE DE69729946T patent/DE69729946T2/en not_active Expired - Lifetime
- 1997-10-14 CN CNB971987548A patent/CN1332661C/en not_active Expired - Fee Related
- 1997-10-14 AU AU49048/97A patent/AU742645B2/en not_active Ceased
- 1997-10-14 PT PT04011516T patent/PT1479385E/en unknown
- 1997-10-14 DK DK97911746T patent/DK0932402T3/en active
- 1997-10-14 IL IL15450197A patent/IL154501A0/en not_active IP Right Cessation
- 1997-10-14 DK DK04011516T patent/DK1479385T3/en active
- 1997-10-14 JP JP51859198A patent/JP2001503395A/en not_active Ceased
- 1997-10-14 IL IL12856897A patent/IL128568A0/en not_active IP Right Cessation
- 1997-10-14 EP EP08159064A patent/EP1977749A1/en not_active Withdrawn
- 1997-10-14 BR BR9712314-5A patent/BR9712314A/en not_active Application Discontinuation
- 1997-10-14 AT AT97911746T patent/ATE271385T1/en active
- 1997-10-14 CA CA002267186A patent/CA2267186C/en not_active Expired - Fee Related
- 1997-10-14 ES ES04011516T patent/ES2308068T3/en not_active Expired - Lifetime
- 1997-10-14 RU RU99110192/15A patent/RU2239429C2/en not_active IP Right Cessation
- 1997-10-14 EP EP97911746A patent/EP0932402B1/en not_active Expired - Lifetime
- 1997-10-14 TR TR1999/00827T patent/TR199900827T2/en unknown
-
1999
- 1999-04-15 NO NO19991793A patent/NO326822B1/en not_active IP Right Cessation
-
2000
- 2000-08-04 HK HK00104885A patent/HK1025518A1/en not_active IP Right Cessation
-
2001
- 2001-02-07 NZ NZ509755A patent/NZ509755A/en not_active IP Right Cessation
-
2004
- 2004-12-16 IL IL16581604A patent/IL165816A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99110192A (en) | METHOD OF USE OF CYCLOXYGENASE-2 INHIBITORS FOR TREATMENT AND PREVENTION OF NEOPLASION | |
US6342510B1 (en) | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist | |
US5990148A (en) | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | |
EP1498140A2 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
US6136839A (en) | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | |
EP1397145B1 (en) | Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders | |
RU2004121147A (en) | APPLICATION OF SOX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR TREATMENT OF INFECTION OF PAPILLOMA VIRUS | |
EP1526869A1 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia | |
MXPA04010888A (en) | Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia. | |
RU99112952A (en) | METHOD OF USE OF CYCLOOXYGENASE-2 INHIBITORS AS AN ANTIANGIOGENIC MEANS | |
JP2004521123A (en) | Combination of uroguanylin and cyclooxygenase-2 inhibitors for intestinal cancer inhibition | |
JP2005501850A5 (en) | ||
US20020035156A1 (en) | Combination therapy in the prevention of cardiovascular disorders | |
JP2005507871A5 (en) | ||
US20070072861A1 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
US20040121961A1 (en) | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer | |
WO2005105099A1 (en) | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors | |
MXPA99009495A (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
JP2001521889A5 (en) | ||
JP2005535657A5 (en) | ||
CA2528634A1 (en) | Treatment of migraine accompanied by nausea | |
CZ9903642A3 (en) | Use of cyclooxygenase-2 inhibitors for prevention of cardiovascular diseases | |
ZA200402088B (en) | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination. |